Cellular Logistics announced recently that it is the recipient of a second Phase I SBIR Grant through the National Institutes of Health, this one worth $337,000.

According to a release, the money will be used to further evaluate the functional immune and angiogenic (blood vessel growth) responses of the company’s Cardiac Fibroblast Matrix product, CFXTM Solus, for the treatment of heart attacks.

“This exciting project will enhance our understanding of the cell-signaling mechanisms of how CFXTM Solus modulates the localized immune system and promotes the repair of damaged heart tissue,” Cellular Logistics CEO Alex Vodenlich said in a statement.

Click here to read the full article.